Celgene International Sàrl, a wholly owned subsidiary of Celgene
Corporation CELG, today announced that the European Commission
(EC) has approved ABRAXANE® (paclitaxel formulated as
albumin-bound nanoparticles, or nab-paclitaxel) in combination with
carboplatin for the first-line treatment of non-small cell lung cancer
in adult patients who are not candidates for potentially curative
surgery and/or radiation therapy.
The ABRAXANE Marketing Authorisation has been updated across 28 member
states in the European Union to include this new indication in non-small
cell lung cancer (NSCLC), adding to the existing indications for the
treatment of metastatic pancreatic and breast cancers.
Lung cancer is the fourth most commonly diagnosed cancer in both men
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in